Logo for Cytokinetics Inc

Cytokinetics Investor Relations Material

Latest events

Logo for Cytokinetics Inc

Q1 2025

Cytokinetics
Logo for Cytokinetics

Q1 2025

6 May, 2025
Logo for Cytokinetics

Q4 2024

27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies

Latest reports from Cytokinetics Inc

Access all reports
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company’s lead drug candidate is tirasemtiv, a fast skeletal muscle activator that is the subject of FORTITUDE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis. It is also developing omecamtiv mecarbil an engineered cardiac myosin activator that is in Phase 2 development for the treatment of systolic heart failure.